G-CSF (GCSF, Granulocyte stimulating factor)

All ESMO 2014 abstracts with reference to G-CSF (GCSF, Granulocyte stimulating factor) are listed below

  • 257O - Intense dose-dense epirubicin (E), paclitaxel (T), cyclophosphamide (C) (iddETC) is highly effective in adjuvant therapy of node-positive breast cancer patients (pts). An analysis of the GBG, AGO-B, and NOGGO study groups
  • 624P - Weekly versus biweekly combination of docetaxel (D)-cisplatin (C)-5FU (F) in advanced gastric cancer and esogastric junction adenocarcinoma (aGC): DoGE Study
  • 702P - Standard clinical practice of FOLFIRINOX (FFX) in advanced/metastatic pancreatic cancer (PC) Patients: A Canadian retrospective registry
  • 782P - Safety of cabazitaxel + prednisone (Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC): Cohort compassionate-use programme (CUP)
  • 858P - Complications during cisplatin based primary chemotherapy in patients with testicular cancer: Is there a need for thromboembolic prophylaxis
  • 860P - Impact of response to induction chemotherapy in patients with germ cell tumors (GCT) receiving salvage high-dose chemotherapy (HDCT): A study of the EBMT Solid Tumors Working Party (STWP)
  • 872TiP - ANZUP 1302: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (P3BEP)
  • 891P - Weekly G-CSF improves the tolerability of weekly paclitaxel-carboplatin. A phase II study of the Belgian Gynaecological Oncology Group (BGOG-ov5)
  • 997P - Results of TPEx (docetaxel, cisplatin, cetuximab) regimen use in first line patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in a single institution
  • 1035P - Induction chemotherapy (ICT) with docetaxel/cisplatin/5-fluorouracil (T/P/F) followed by chemoradiotherapy with Cisplatin (CRTP) vs bioradiotherapy with Cetuximab (RTCx) for unresectable locally advanced head & neck cancer (ULAHNC): Preliminary results on toxicity a TTCC group trial
Last update: 02 September 2014